Watertown, MA – According to filings with the U.S. Securities and Exchange Commission, Acrivon Therapeutics is raising $100,000,000.00 in new funding. Sources indicate as part of senior management President, Peter Blume-Jensen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Acrivon Therapeutics
Acrivon is developing best-in-class targeted therapies to improve the lives of patients. At the frontier of proteomics, Acrivons unprecedented patient selection method represents a paradigm change in precision oncology drug development. Powered by our AP3 platform, we match drug mechanisms to the biologic drivers of cancer in patients, uncovering drug sensitivity not achievable through genomics. Aiming to address the worlds most common and pressing cancers, Acrivons technology and pipeline is built to improve patient outcomes. This is possible due to our unique OncoSignature patient selection test, which is designed to accurately match our therapeutics with patients to ensure they will truly benefit from our treatments.

To learn more about Acrivon Therapeutics, visit http://acrivon.com/

Contact:
Peter Blume-Jensen, President
617-207-8979
https://www.linkedin.com/in/peter-blume-jensen-462913/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved